Clinical Trials Logo

Psychomotor Agitation clinical trials

View clinical trials related to Psychomotor Agitation.

Filter by:

NCT ID: NCT01113710 Completed - Clinical trials for Idiopathic Restless Legs Syndrome

Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise

RLS-Practise
Start date: May 2010
Phase: N/A
Study type: Observational

This non-interventional observational study is designed to gain data for Neupro® in restless legs syndrome (RLS) under real life conditions in line with the summary of product characteristics (SmPC) related to effectiveness, tolerability and switching practice from other dopaminergic drugs as well as titration schemes.

NCT ID: NCT01109537 Completed - Clinical trials for Restless Legs Syndrome

Altered Brain GABA and Glutamate in Restless Legs Syndrome

RLS
Start date: April 2010
Phase: N/A
Study type: Observational

The purpose of the study is to understand the brain chemistry of people with Restless Legs Syndrome (RLS). The primary hypothesis is that patients with RLS will have reduced GABA levels in their Thalamus and elevated Glutamate levels in their Anterior Cingulate Cortex. The study will use MRS imaging to examine the regional levels of these neurochemicals, GABA and Glutamate, in the brain.

NCT ID: NCT01084551 Completed - Clinical trials for Idiopathic Restless Legs Syndrome

Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Start date: February 2010
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the clinical efficacy and safety of SPM962 in patients with restless legs syndrome (RLS) with once-daily repeated doses of 4.5mg and 6.75mg during a 13-week dose-titration and maintenance period. This is a multi-center, randomized, placebo-controlled, double-blind, 3-armed parallel group comparison study. Efficacy will be determined by investigating the superiority of SPM962 to placebo in terms of the primary efficacy variable, change in International Restless Legs Syndrome Rating Scale (IRLS) total score from baseline to the end of the dose-maintenance period.

NCT ID: NCT01061372 Withdrawn - Clinical trials for Restless Legs Syndrome

12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects

Start date: May 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess efficacy and safety of pregabalin in treating moderate to severe Restless Legs Syndrome in comparison to placebo.

NCT ID: NCT01050478 Completed - Acute Disease Clinical Trials

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Start date: March 2010
Phase: Phase 4
Study type: Interventional

This study will investigate the effect of paliperidone ER (in combination with or without benzodiazepines) in patients presenting with symptoms of agitation and/or aggression in the context of psychosis, and will generate data regarding both efficacy and safety in the acute setting.

NCT ID: NCT00996944 Terminated - Clinical trials for Restless Legs Syndrome

Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)

Start date: November 30, 2009
Phase: Phase 2
Study type: Interventional

This is a multicenter, placebo controlled, parallel group, double-blind, randomized comparison study to evaluate the efficacy and safety of ropinirole IR tablets orally administered for 12 weeks in patients with symptomatic restless legs syndrome associated with Chronic kidney disease (CKD) managed with haemodialysis (including haemofiltration and haemodiafiltration) (hereinafter referred to as "uRLS"), to evaluate the efficacy and safety of long-term administration of ropinirole IR tablets, and assess the effect on the steady state pharmacokinetics in the long-term administration period of ropinirole IR tablets.

NCT ID: NCT00991276 Completed - Clinical trials for Restless Legs Syndrome

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of pregabalin and pramipexole versus placebo in the treatment of restless legs syndrome and associated sleep disturbance.

NCT ID: NCT00990769 Completed - Emergence Agitation Clinical Trials

The Effect of Depth of Anesthesia as Measured by Bispectral Index (BIS) on Emergence Agitation in Children

Start date: September 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether depth of anesthesia has an effect on emergence agitation (EA) in children age 2 - 8 years old. EA is a common problem in pediatric patients who receive general anesthesia with inhaled anesthetics, and the effect of depth of anesthesia on EA has not been studied. The study will randomize 40 children undergoing ophthalmologic surgery under general anesthesia to either light anesthesia (BIS 55-60) or deep anesthesia (BIS 40-45). EA will be measured by the peak Pediatric Assessment of Emergence Delirium (PAED) score in the recovery room, which rates agitation behaviors on a scale of 0 - 20. The hypothesis is that light anesthesia is associated with more EA.

NCT ID: NCT00949858 Completed - Clinical trials for Obstructive Sleep Apnea

New Data Analysis Methods for Actigraphy in Sleep Medicine

Start date: July 2009
Phase: N/A
Study type: Observational

The purpose of this study is to develop statistical and informatics tools for analyzing and visualizing Acticalâ„¢ (actigraphy) data linked to fatigue in Sleep Medicine Center patients.

NCT ID: NCT00949806 Completed - Clinical trials for Restless Legs Syndrome

Restless Legs Syndrome Treatment With Botulinum Toxin

SOXIS
Start date: August 2009
Phase: Phase 2
Study type: Interventional

Restless Legs Syndrome (RLS) is a common sensori-motor disorder that causes sensory discomfort and motor restlessness, most often in the legs, which improves with movement. Although medications are available to treat the disorder, many people either experience side effects that prevent them from continuing on the medication or do not sufficiently respond to current RLS medications. Recently, botulinum toxin type A (BNT) has been reported to relief RLS in patients with severe symptoms but this was not confirmed by other anecdotal reports. The investigators propose to test the efficacy of BNT on RLS symptoms by designing a more controlled study. Ultimately, this may lead to extend the therapeutic arsenal of this disorder.